SCHEMBL515643

SCHEMBL515643

O=C(CCC[C@@H](O)c1ccc(F)cc1)N1C(=O)OC[C@@H]1c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC18A3 Q16572 1/20 0.44
NAAA Q02083 2/20 0.43
NPC1 O15118 1/20 0.40
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
HPGD P15428 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
ALDH1A1 P00352 1/20 0.38
GAA P10253 1/20 0.38
HTT P42858 1/20 0.38
SLC6A3 Q01959 5/20 0.37
CACNA1F O60840 1/20 0.37
DRD1 P21728 1/20 0.37
DRD4 P21917 1/20 0.37
DRD5 P21918 1/20 0.37
HRH2 P25021 1/20 0.37
ADRA1D P25100 1/20 0.37
HTR2A P28223 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2050725 1.00 SLC18A3 (0.44) SLC18A3NAAANPC1LMNATP53
SCHEMBL541628 1.00 SLC18A3 (0.44) SLC18A3NAAANPC1LMNATP53
SCHEMBL515189 1.00 SLC18A3 (0.44) SLC18A3NAAANPC1LMNATP53
SCHEMBL2048861 1.00 SLC18A3 (0.44) SLC18A3NAAANPC1LMNATP53
SCHEMBL542243 1.00 SLC18A3 (0.44) SLC18A3NAAANPC1LMNATP53
SCHEMBL514845 1.00 SLC18A3 (0.44) SLC18A3NAAANPC1LMNATP53
SCHEMBL3493992 1.00 SLC18A3 (0.44) SLC18A3NAAANPC1LMNATP53
SCHEMBL28883791 1.00 SLC18A3 (0.44) SLC18A3NAAANPC1LMNATP53
SCHEMBL27967862 0.92 NAAA (0.46) NAAANPC1LMNATP53HPGD
SCHEMBL27967864 0.92 NAAA (0.46) NAAANPC1LMNATP53HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2414339-B1 KINETIC RESOLUTION OF (4S)-4-PHENYL-3-[5(RS)-(4-FLUOROPHENYL)-5-HYDROXYPENTANOYL]-1,3 OXAZOLIDIN 2-ONE TO (5S) ISOMER VIA LIPASE CATALYZED ENANTIOSELECTIVE ESTERIFICATION OF THE (5R) ISOMER LUPIN LTD (IN) 2013-01-16 EP claimed
EP-2414339-A1 KINETIC RESOLUTION OF (4S)-4-PHENYL-3-Ý5(RS)-(4-FLUOROPHENYL)-5-HYDROXYPENTANOYL¨-1,3 OXAZOLIDIN 2-ONE TO (5S) ISOMER VIA LIPASE CATALYZED ENANTIOSELECTIVE ESTERIFICATION OF THE (5R) ISOMER Lupin Ltd. (IN) 2012-02-08 EP claimed
US-20120028340-A1 KINETIC RESOLUTION OF (4S) -- 4- PHENYL -- 3- [(5RS)-5-(4-FLUROPHENYL)-5- HYDROXYPENTANOYL] --1,3-OXAZOLIDIN-2-ONE TO THE (5S) ISOMER VIA LIPASE CATALYZED ENANTIOSELECTIVE ESTERIFICATION OF THE (5R) ISOMER LUPIN LIMITED (IN) 2012-02-02 US claimed
WO-2010113184-A1 KINETIC RESOLUTION OF (4S)-4-PHENYL-3-[5(RS)-(4-FLUOROPHENYL)-5-HYDROXYPENTANOYL] -1,3 OXAZOLIDIN 2-ONE TO (5S) ISOMER VIA LIPASE CATALYZED ENANTIOSELECTIVE ESTERIFICATION OF THE (5R) ISOMER LUPIN LIMITED (IN) 2010-10-07 WO claimed
CN-115184485-A Ezetimibe prodrug impurity detection method 南京优科生物医药股份有限公司 2022-10-14 CN disclosed
EP-2417183-B1 CURABLE COMPOSITION HENKEL AG & CO KGAA (DE) 2013-01-16 EP disclosed
EP-2414339-B1 KINETIC RESOLUTION OF (4S)-4-PHENYL-3-[5(RS)-(4-FLUOROPHENYL)-5-HYDROXYPENTANOYL]-1,3 OXAZOLIDIN 2-ONE TO (5S) ISOMER VIA LIPASE CATALYZED ENANTIOSELECTIVE ESTERIFICATION OF THE (5R) ISOMER LUPIN LTD (IN) 2013-01-16 EP disclosed
EP-2414339-A1 KINETIC RESOLUTION OF (4S)-4-PHENYL-3-Ý5(RS)-(4-FLUOROPHENYL)-5-HYDROXYPENTANOYL¨-1,3 OXAZOLIDIN 2-ONE TO (5S) ISOMER VIA LIPASE CATALYZED ENANTIOSELECTIVE ESTERIFICATION OF THE (5R) ISOMER Lupin Ltd. (IN) 2012-02-08 EP disclosed
EP-2414339-A1 KINETIC RESOLUTION OF (4S)-4-PHENYL-3-Ý5(RS)-(4-FLUOROPHENYL)-5-HYDROXYPENTANOYL¨-1,3 OXAZOLIDIN 2-ONE TO (5S) ISOMER VIA LIPASE CATALYZED ENANTIOSELECTIVE ESTERIFICATION OF THE (5R) ISOMER Lupin Ltd. (IN) 2012-02-08 EP disclosed
US-20120028340-A1 KINETIC RESOLUTION OF (4S) -- 4- PHENYL -- 3- [(5RS)-5-(4-FLUROPHENYL)-5- HYDROXYPENTANOYL] --1,3-OXAZOLIDIN-2-ONE TO THE (5S) ISOMER VIA LIPASE CATALYZED ENANTIOSELECTIVE ESTERIFICATION OF THE (5R) ISOMER LUPIN LIMITED (IN) 2012-02-02 US disclosed
US-20120028340-A1 KINETIC RESOLUTION OF (4S) -- 4- PHENYL -- 3- [(5RS)-5-(4-FLUROPHENYL)-5- HYDROXYPENTANOYL] --1,3-OXAZOLIDIN-2-ONE TO THE (5S) ISOMER VIA LIPASE CATALYZED ENANTIOSELECTIVE ESTERIFICATION OF THE (5R) ISOMER LUPIN LIMITED (IN) 2012-02-02 US disclosed
WO-2010113184-A1 KINETIC RESOLUTION OF (4S)-4-PHENYL-3-[5(RS)-(4-FLUOROPHENYL)-5-HYDROXYPENTANOYL] -1,3 OXAZOLIDIN 2-ONE TO (5S) ISOMER VIA LIPASE CATALYZED ENANTIOSELECTIVE ESTERIFICATION OF THE (5R) ISOMER LUPIN LIMITED (IN) 2010-10-07 WO disclosed
WO-2010113184-A1 KINETIC RESOLUTION OF (4S)-4-PHENYL-3-[5(RS)-(4-FLUOROPHENYL)-5-HYDROXYPENTANOYL] -1,3 OXAZOLIDIN 2-ONE TO (5S) ISOMER VIA LIPASE CATALYZED ENANTIOSELECTIVE ESTERIFICATION OF THE (5R) ISOMER LUPIN LIMITED (IN) 2010-10-07 WO disclosed
US-7586015-B2 Process for the preparation of 1,3,2-oxazaborolidine compounds ZACH SYSTEM (FR) 2009-09-08 US disclosed
US-7586015-B2 Process for the preparation of 1,3,2-oxazaborolidine compounds ZACH SYSTEM (FR) 2009-09-08 US disclosed
US-20080139851-A1 R2, R3, R4 and R5 are especially a hydrogen atom or an alkyl,wherein the following are reacted in two steps:a) a boric precursor compound with an acetal compound to give a boronate compound; and) the boronate compound with an amino alcohol compound PPG-SIPSY (FR) 2008-06-12 US disclosed
US-20080139851-A1 R2, R3, R4 and R5 are especially a hydrogen atom or an alkyl,wherein the following are reacted in two steps:a) a boric precursor compound with an acetal compound to give a boronate compound; and) the boronate compound with an amino alcohol compound PPG-SIPSY (FR) 2008-06-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139851-A1 R2, R3, R4 and R5 are especially a hydrogen atom or an alkyl,wherein the following are reacted in two steps:a) a boric precursor compound with an acetal compound to give a boronate compound; and) the boronate compound with an amino alcohol compound ADH1A, ADH1C, ADH5 SLC18A3 2597/4885NAAA 2621/4885NPC1 4426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.